FDA Places RGX-121 on Clinical Hold The US Food and Drug Administration has placed Regenxbio’s experimental gene therapy RGX-121 on clinical hold. The company announced the decision on Monday. The FDA action follows spinal scans that showed abnormalities in five patients who received the treatment. Regenxbio shares fell more than 24 percent in premarket trading… Continue reading RGX-121 Clinical Hold Issued After Spinal Abnormalities Found
RGX-121 Clinical Hold Issued After Spinal Abnormalities Found